NEW YORK, NY / ACCESSWIRE / October 5, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=9825&wire=1
Lead Plaintiff Deadline: November 2, 2020
Class Period: February 11, 2020 - August 10, 2020
Allegations against FENC include that: (1) the manufacturing facilities for PEDMARK, the Company's sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Lexinfintech Holdings, Ltd. (NASDAQ:LX)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/lexinfintech-holdings-ltd-loss-submission-form?prid=9825&wire=1
Lead Plaintiff Deadline: November 9, 2020
This lawsuit is on behalf of shareholders who purchased or otherwise acquired: (a) Lexin American depositary shares pursuant and/or traceable to the Company's initial public offering conducted on or about December 21, 2017; or (b) Lexin securities between December 21, 2017 and August 24, 2020.
Allegations against LX include that: (1) LexinFintech reported artificially low delinquency rates by giving borrowers in default new funds to make payments; (2) the Company's business model exposes shareholders to enormous losses by prioritizing Chinese lenders for off-balance sheet loans; (3) the Company exaggerated its user base; (4) the Company was facilitating direct peer to peer lending contrary to Chinese law; (5) the Company engaged in undisclosed related party transactions; (6) the Company lacked adequate internal controls; and (7) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Tactile Systems Technology, Inc. (NASDAQ:TCMD)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/tactile-systems-technology-inc-loss-submission-form?prid=9825&wire=1
Lead Plaintiff Deadline: November 30, 2020
Class Period: May 7, 2018 - June 8, 2020
Allegations against TCMD include that: (1) while Tactile publicly touted a $4 plus billion or $5 plus billion market opportunity, in truth, the total addressable market for Tactile's pneumatic compression devices was materially smaller; (2) to induce sales growth and share gains, Tactile and/or its employees were engaged in illicit and illegal sales and marketing activities in violation of applicable federal and state rules and public payer regulations; (3) the foregoing illicit and illegal sales and marketing activities increased the risk of a Medicare audit of Tactile's claims and criminal and civil liability; (4) Tactile's revenues were in part the product of unlawful conduct and thus unsustainable; and that as a result of the foregoing, (5) Defendants' public statements, including Tactile's year-over-year revenue growth, the purported growth drivers, and the effectiveness of Tactile's internal controls over financial reporting were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email firstname.lastname@example.org or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: